Experimental combo therapy targets Hard-to-Treat skin cancer
NCT ID NCT06940440
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new cancer vaccine called IFx-Hu2.0 given together with the immunotherapy drug pembrolizumab (Keytruda) in 9 adults with advanced or metastatic Merkel cell carcinoma. The vaccine is injected directly into a tumor, and pembrolizumab is given through an IV. The main goals are to see if the combination is safe and if it is possible to inject the vaccine into internal tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IFx-Hu2.0 (a cancer vaccine injected into a tumor) and pembrolizumab (an immunotherapy drug given by IV)
- What this could lead to
- If it works, this could point toward a new combination treatment for advanced Merkel cell carcinoma that is hard to treat.
- What could go wrong
- This is a very early Phase 1 trial with only 9 people, so it is mainly checking safety and whether the injection is possible. It is too small and early to know if it will help patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC MERKEL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
RECRUITINGTampa, Florida, 33612, United States
-
University of Wisconsin Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.